BackGalectin Therapeutics Overview

Galectin Therapeutics Selling, General & Admin

Selling, General & Admin expenses for GALT.

Quarterly SG&A Expenses

$1.85M
↑ 30.74% YoY

As of Mar 31, 2026

Annual SG&A Expenses (TTM)

$6.23M
↑ 9.84% YoY

Trailing 12 months ending Mar 31, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin